Browse through our press and news section by category:

08.11.2013

SCHOTT introduces TopPac 20 ml prefillable polymer syringe for infusion therapy

Picture ID: 216987 SCHOTT will be expanding its range of TopPac polymer syringes to include a 20 Milliliter (ml) format that can be used in combination with syringe pumps for infusion therapy.

St. Gallen, November 8, 2013 – SCHOTT will be expanding its range of TopPac polymer syringes to include a 20 Milliliter (ml) format that can be used in combination with syringe pumps for infusion therapy. TopPac prefillable syringes (PFS) are compatible with various syringe pumps, and the exact outer diameter enables automated recognition by the syringe pumps. They are also compatible with the IV devices, i.e. needle less luer access devices (NLADs). Optimized siliconization ensures consistent gliding forces for smooth drug application and also reduces the interaction of silicone with the drug during the shelf life. The new TopPac 20 ml PFS will be available from December 2013 on. With this move, SCHOTT is enhancing its portfolio for large volume syringes for intensive care which already includes a 10 ml and 50 ml format. SCHOTT TopPac PFS are available in the sizes 1 to 50ml.

Improved safety in infusion therapy
Healthcare professionals often rely on infusion therapy in clinical settings such as intensive care units, critical care, emergency rooms and surgery centers.The most common medications administered through syringe pumps are pain medications, anesthetics and cardiovascular medications. As the majority of these medications have a narrow margin of safety, the delivery of the right drug in the right concentration and right dose is critical. Even seemingly minor errors may cause significant harm to a patient. Current practices often involve a manual multi-step preparation process for transferring drugs from their primary containers like ampoules or vials to disposable syringes – a multi-step manual preparation process that is prone to human error. Using prefilled syringes such as TopPac simplifies the preparation process and reduces the likelihood of medication errors significantly.

SCHOTT has designed TopPac syringes to support the zero tolerance practice for infusion-related adverse events. The syringes are pre-filled with the accurate dose of the correct medication by pharmaceutical companies to reduce the risk of medication errors significantly. This also ensures timely delivery of medications because the medical personal can prepare and administer the drug much more quickly. An integrated Luer Lock assures a leak-proof connection between the syringe and the IV line and reduces the risk of unintended disconnection. Due to the fact that they are made of polymer material these syringes offer a high break resistance.

SCHOTT manufactures TopPac in a fully integrated clean room production environment. This ensures low contamination and particle levels without washing. The syringes are supplied in common nests and tubs, which can be integrated into existing filling lines. The transparency of the COC raw material also facilitates visual inspections on filling lines. All in all, the benefits of TopPac syringes translate into reduced total cost of ownership for pharmaceutical companies and health care facilities.

About SCHOTT

SCHOTT is an international technology group with more than 125 years of experience in the areas of specialty glasses and materials and advanced technologies. SCHOTT ranks number one in the world with many of its products. Its core markets are the household appliance, solar power, pharmaceuticals, electronics, optics, transportation and architecture industries. The company is strongly committed to contributing to its customers’ success and making SCHOTT an important part of people’s lives with high-quality products and intelligent solutions. SCHOTT is committed to managing its business in a sustainable manner and supporting its employees, society and the environment. The SCHOTT Group maintains close proximity to its customers with manufacturing and sales units in 35 countries. Its workforce of around 16,000 employees generated worldwide sales of approximately 2 billion euros for the 2011/2012 fiscal year. SCHOTT AG, with its headquarters in Mainz (Germany) is owned by the Carl Zeiss Foundation.